A Peninsula drug developer's stock ballooned more than 100% in after-hours trading Monday after it disclosed early data from a midstage clinical trial of a drug designed to treat the autoimmune kidney disease lupus nephritis.
Kezar Life Sciences Inc. (NASDAQ: KZR) said lupus nephritis patients responded well — including some with a complete response — after 24 weeks of treatment with the company's drug zetomipzomib.
Lupus nephritis is a type of kidney disease caused by systemic lupus, where…
